Keeping Track: Rebyota, Rezlidhia Rev Up US FDA Approvals; New Sponsors Sought For Poziotinib, Brexafemme

 
• By Bridget Silverman
  
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers